Takeda to license Trianni mAb discovery platform

By Zachary Brennan

- Last updated on GMT

Takeda opts for mAb discovery platform
Takeda opts for mAb discovery platform

Related tags Gene

Takeda has entered into a license agreement for the use of the Trianni Mouse, a monoclonal antibody discovery platform. 

Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with access to a complete human antibody repertoire that has been optimized for the isolation of fully human therapeutics. 

Matthias Wabl, Ph.D., Chairman and CEO of Trianni, told Biopharma-reporter.com that “for antibody drugs, you want the antibodies to be completely human and you want the complete repertoire that humans can make​.

“So we took out the genes that encode for antibodies in mice, and we inserted the human genes – but we didn’t do it in a way that other companies have done it. We constructed the selection of genes on a computer and only made human some parts​.

We’ve synthesized large pieces of DNA, and interspersed within these sequences, snippets of human DNA​,” Wabl said. “We have synthesized large pieces of DNA and we took the mouse sequences which we previously took out and replaced parts that encode human antibodies with human DNA​.”

mAb Growth

mAb development has seen rapid development recently, with companies such as Pfizer​, Regeneron​ and GlaxoSmithKline​ moving into the market.

Monoclonal antibodies are now the ‘hot’ drugs – the targets are three fold: infectious disease, antibiotic resistant-bacteria, and then antibodies used against cancer,”​ he added. But no drugs have been generated from the out-licensing of Trianni’s discovery platform yet.

First-generation human antibody mice were made in the 1990s…but they didn’t have the full repertoire and were restricted in their usefulness​,” Wabl said. “Because antibodies are specific…the more antibodies the mouse can make, the better off you are. The important thing is that the mouse makes human antibodies​.”

With its many distinctive features, most notably a full repertoire expressed from chemically synthesized gene segments, we are confident the platform will prove highly productive for Takeda​,” he added. 

We are excited to add Trianni’s transgenic mice to Takeda’s repertoire of platform technologies for the generation of therapeutic antibodies​,” said Tetsuyuki Maruyama, Ph.D., General Manager of Pharmaceutical Research Division of Takeda. “Takeda has a growing biologics pipeline and the Trianni Mouse is a natural addition to enhance our ongoing research capabilities in the area​.”

Related news

Show more

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us